---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044756"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:44:12.368196+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical Q3 revenue $27.9M (+12% YoY); reaffirms FY2024 guidance $116-120M

## Summary
- Revenue $27.9M (+12% YoY); YTD revenue $85.8M (+36% YoY).
- Net loss $5.0M vs net income $9.2M in Q3 2023, which included $11M bargain purchase gain.
- Adjusted EBITDA loss $196K vs $440K gain; gross margin 58.4% down from 61.3%.
- Reaffirmed FY2024 revenue guidance $116-120M, representing 27-31% annual growth.
- Launched OsteoVive+ and Cortera system; signed license agreement for minimum $5.25M in fees.

## SEC filing metadata
- accession: 0001493152-24-044756
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315224044756/0001493152-24-044756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315224044756/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044756
- JSON: https://secwatch.observer/filing/0001493152-24-044756.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.